Information Provided By:
Fly News Breaks for January 7, 2020
BLFS
Jan 7, 2020 | 16:10 EDT
Stephens analyst Jacob Johnson initiated coverage of BioLife Solutions with an Overweight rating and $23 price target. He believes BioLife, as a provider of tools to cell and gene therapy companies, is well-positioned to benefit from expected growth in cell and gene therapy spending.
News For BLFS From the Last 2 Days
There are no results for your query BLFS